

20 MICRONS[®] L I M I T E D

347, GIDC Industrial Estate, Waghodia - 391760, Dist. Vadodara, Gujarat, India.

28th May, 2018

To :

BOMBAY STOCK EXCHANGE LIMITED Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Fort, MUMBAI - 400 001. <u>SCRIP CODE : 533022</u>	NATIONAL STOCK EXCHANGE OF INDIA LIMITED Listing Department Exchange Plaza, Bandra - Kurla Complex, Bandra [East], MUMBAI - 400 051. <u>SCRIP CODE : 20MICRONS</u>
--	--

Dear Sirs,

Re : Press Release.

In continuation of our letter dated 24.05.2018, we are sending herewith Press Release on the Financial Results of the Company for the Quarter/Year ended 31.03.2018.

We now request you to arrange to take note of the above.

Thanking you,

**Yours faithfully
20 Microns Limited**


**[Anuja K. Muley]
Company Secretary**



Encl. : as above.

An ISO 9001 : 2008 Certified Company

Regd. Office : 9-10, GIDC Ind. Estate, Waghodia - 391 760 Dist. Vadodara, Gujarat, INDIA.

T: +91 - 2668 292297 **W:** www.20microns.com **E:** baroda@20microns.com

CIN : L99999GJ1987PLC009768



20 Microns Ltd.

CIN:L99999GJ1987PLC009768

Registered Office:9-10, GIDC, Industrial Estate, Waghodia - 391760, Dist. Vadodara, Gujarat, India

FY2018 Performance Highlights(Consolidated)

Total Revenue reported at Rs.4339.23million, up 5.45%

EBITDA at Rs. 622.53million, up 8.78%

PAT at Rs.188.35million, up 18.92%

Vadodara,24thMay,2018:20 Microns Ltd, one of the India's leading producer of Industrial Minerals,announced its financial results for the quarter and year ended onMarch31 2018.

Particulars (Rs. mn)	Quarter Ended Standalone			Full Year Standalone			Full Year Consolidated		
	FY18 Q4	FY17 Q4	Shift%	FY18	FY17	Shift %	FY18	FY17	Shift %
Total Revenue	1027.76	889	15.61%	3921.29	3741.67	4.80%	4339.23	4114.87	5.45%
EBITDA	145.31	83.97	73.05%	557.98	510.44	9.31%	622.53	572.27	8.78%
EBITDA Margin %	14.37%	9.51%	486 bps	14.36%	13.73%	63 bps	14.43%	13.97%	46 bps
PBT	55.48	8.66	540.65%	237.95	193.3	23.10%	280.39	231.01	21.38%
PAT	33.67	6.77	397.34%	158.8	131.59	20.68%	188.35	158.39	18.92%
PAT Margin %	3.28%	0.76%	251 bps	4.05%	3.52%	53 bps	4.34%	3.85%	49 bps

FY18Q4 & 12M (Consolidated) Performance Overview

- Total Revenue for Q4 FY18 was Rs. 1027.76 million as against Rs.889 million in Q4 FY17. Revenue for the FY18 was Rs. 4339.23 million as against Rs.4114.87 million in FY17. The revenues posted registered a gradual growth since the company has been

focusing on the organic growth, value added products & robust price-mix effect in all business segments.

- ❑ *EBIDTA improved by 73.05 % YoY to Rs. 145.31 million in Q4 FY18 from Rs. 83.97 million in Q4 FY17. While for FY18 EBIDTA was at Rs. 622.53 million with EBIDTA margin of 14.43 % marginally higher due to robust performance driven by healthy volumes and better realization, along with sale of value added products contributing higher margins.*
- ❑ *PAT increased by 397.34% QoQ to Rs. 33.67 million in Q4 FY18 versus Rs. 6.77 million in Q4 FY17 as the Company continues to focus on value added products & volumes. The PAT for FY18 stood at Rs. 188.35 million compare to Rs. 158.39 million in FY17.*

Operational Update

- ❑ *Company has dynamically participated in 5 exhibitions and trade shows which are regarded and considered to be the premier and finest in the industry covering an extensive product portfolio, where there were eminent participants and visitors from across the globe and showcased as the forefront in developing solutions and innovative products.*
- ❑ *Company's debt-equity ratio came down from 1.01 in 2017 to 0.79 in 2018.*

Management Comments

Commenting on the results, Mr. Atil Parikh said:

- ❑ *During the fourth quarter, 20 Microns continued to benefit from improving markets, its development strategy and innovation policy. FY19 should therefore be another year of progress in net income from current operations at current market conditions and will further invest in its growth, strengthen its competitiveness. We expect our revenues to grow in the range of 15% and margins to expand by 100 bps across the revenue board. We propose to reduce our long term debt with better internal accruals and thereby leading to reduction in the finance cost. Our company will execute some minor capex for the next 2-3 years to be funded through internal accruals resulting in increase of the capacity and de bottleneck the existing infrastructure. In the long run, we have a vision of enhancing our global presence and create a strong brand in the domestic geography.*
- ❑ *FY18 was a major year in the rollout of 20 Microns strategy. Our Group broadened its business portfolio by adding value added products. The focus over the next few years for 20 Microns is to improve cash flow realisation/EBITDA and reduce its debt which is about Rs1,144million. The improvement in realisation will be driven by higher capacity utilization, growth in **CMM(Chemically Modified Minerals), Functional Additives (FA)**, & other speciality minerals etc, minimizing waste generation across its plants. We are actively pursuing efforts in this direction and developing product*

lines which are meant to transform the waste generated by its plants as inputs for various industries. 20 Microns will benefit from the quality of its business model, its operational discipline and capital expenditure on production capacities, as well as from innovation, excellence programs and internal efficiency.

About 20 Microns Ltd.

20 Microns Ltd, the pioneers in the field of Industrial Minerals in India, bringing the organized concept of Micronization and tapping various different Industrial Micronized and Sub-Micronized Minerals under its portfolio. Since few years back, 20 Microns also delved into the world of Specialty Minerals, Chemicals and Performance Additives catering to the niche segments and formulations made through advanced and superior technology to serve our existing and new customer base for diverse applications.

With a devoted R&D and Product Application Centre, we are committed to continuously innovate and offer a variety of products catering to numerous applications and formulations enhancing the product performances and delivering high value added functional solutions to various industries.

20 Microns, through its innovative & continuous R&D thrives to add further more products into its basket of products with continuous interaction with its domestic and international customers which has always proven to be our key to success.

For further information on the Company, please visit www.20microns.com:

For further information contact:

Mr. Atil Parikh
20 Microns Ltd.

Contact: +91 22 2577 1325/ 2577 1350

E-mail: atil@20microns.com

Vinayak Shirodkar / Krunal Shah

KDA Strategic Advisors LLP

Contact: +91 22 2615 0007/2611 0007

Email: vinayaks@kdg.co.in/krunals@kdg.co.in

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. 20 MICRONS LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCES.

20 Microns Nano Minerals Limited (the "Issuer Company") is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make a public issue of its Equity Shares and has filed a Draft Red Herring Prospectus ("DRHP") dated March 19, 2018 on the SME Platform of the National Stock Exchange of India Limited ("NSE EMERGE"). The DRHP is available on the website of NSE EMERGE at <https://www.nseindia.com/emerge> and the website of the Book Running Lead Manager, Vivro Financial Services Private Limited at [*]. Investors should note that investment in securities involves a high degree of risk and are requested to refer to the DRHP, including the section titled "Risk Factors" beginning on page 17 of the DRHP. Potential investors should not rely on the DRHP filed with the Stock Exchange for making any investment decision.